{"id":60787,"date":"2015-10-21T18:55:08","date_gmt":"2015-10-21T22:55:08","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=60787"},"modified":"2015-10-21T19:01:43","modified_gmt":"2015-10-21T23:01:43","slug":"damned-sure-important","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2015\/10\/21\/damned-sure-important\/","title":{"rendered":"damned sure important&#8230;"},"content":{"rendered":"\n<p align=\"justify\" class=\"small\">I wish that what I write about could always be interesting, but I just can&#8217;t bring it off. Writing is my way of gathering my thoughts, and sometimes that&#8217;s pretty boring, even to me. My daughter who named this blog has apologized for her sarcasm, but to be honest, I&#8217;m very appreciative. The injunction to be interesting is just too daunting. So here&#8217;s some more details about that last post &#8211; what that EMA email clarified about what regulatory documents they are actually going to make available. It&#8217;s a two phase process, and we&#8217;re in <font color=\"#200020\">phase 1<\/font>. All we have right now from the clinical drug trials are the registration documents from a registry like clinicaltrials.gov and a published paper [if one is even published]. The inadequacy of that level of access is legend. <\/p>\n<p align=\"justify\" class=\"small\"><u><font color=\"#200020\">What the European Medicines Agency is <u>plann<\/u>ing to make available<\/font><\/u>:<br \/>  I&#8217;ve used some version of this diagram to relate the documents to the actual process of the trial itself.  <\/p>\n<p align=\"center\" class=\"small\"><img decoding=\"async\" width=\"270\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/clinical-trial-demo-5.gif\" \/><\/p>\n<p align=\"justify\" class=\"small\">The <font color=\"#200020\">PROTOCOL<\/font> and the <font color=\"#200020\">SAP <\/font>[<font color=\"#200020\">STATISTICAL ANALYSIS PLAN<\/font>] are the two major documents that are <em><font color=\"#200020\">a priori<\/font><\/em> [written <em><font color=\"#200020\">before<\/font><\/em> the trial begins] and shouldn&#8217;t be changed without good reason along the way [and if they are, it needs to be by formal amendment filed with the Institutional Review Board]. The confusion in all the deliberations is about what is in the <font color=\"#200020\">CSR<\/font> [<font color=\"#200020\">Complete Study Report<\/font>]. There is a long narrative, much more detailed than any published paper could ever be. And then there are Appendices. In the EMA system, the <font color=\"#200020\">PROTOCOL<\/font> is an appendix. The <font color=\"#200020\">STATISTICAL ANALYSIS PLAN<\/font> is an appendix. The <font color=\"#200020\">SAMPLE CASE REPORT FORMS<\/font> are an appendix. The compiled raw data [<font color=\"#200020\">INDIVIDUAL PARTICIPANT DATA<\/font>] is spread among several appendices. And finally, the actual <font color=\"#200020\">CASE REPORT FORMS <\/font>[<font color=\"#200020\">CRF<\/font>] filled out by the subjects or study personnel might be an appendix. So when people say CSR, it matters what appendices are actually included. Here&#8217;s what that email [<a href=\"http:\/\/1boringoldman.com\/index.php\/2015\/10\/21\/some-clarity\/\" target=\"_blank\">some clarity?&hellip;<\/a>] and the referenced documents said:  <\/p>\n<p align=\"center\" class=\"small\"><img decoding=\"async\" width=\"270\" border=\"0\" src=\"http:\/\/1boringoldman.com\/images\/clinical-trial-demo-7.gif\" \/><\/p>\n<p align=\"justify\" class=\"small\">After a drug has completed the regulatory process, the documents in the phase 1 box above will be made available. The availability or conditions for availability of the various appendices with the raw data will be decided at a later date [phase 2].<\/p>\n<p align=\"justify\" class=\"small\"><u><font color=\"#200020\">Why I have perseverated [been hung up on] this point<\/font><\/u>:<br \/> With Study 329, the CSR narrative was available and with that, one could tell something[s] was\/were fishy. The <font color=\"#200020\">PROTOCOL\/STATISTICAL ANALYSIS PLAN<\/font>&nbsp; became available along the way. In terms of <em><font color=\"#200020\">efficacy<\/font><\/em>, we needed the <font color=\"#200020\">IPD<\/font> to do the definitive analysis that we published in September [<a href=\"http:\/\/www.bmj.com\/cgi\/doi\/10.1136\/bmj.h4320\" target=\"_blank\">Restoring    Study 329: efficacy and harms of paroxetine and                  imipramine in treatment of major depression in adolescence<\/a>]. With only the article to go on, one could only speculate and suspect. It was over three years after the article was published that the <font color=\"#200020\">CSR<\/font> became available, and eleven years before the <font color=\"#200020\">IPD<\/font> was public. <strong><font color=\"#200020\">If the information in the phase 1 box above is available on every drug in a timely fashion, anyone can look to see if the reported article follows the protocol directed outcome variables using the pre&middot;specified analytic techniques. That is a massive improvement over what we have now.<\/font><\/strong> <\/p>\n<p align=\"justify\" class=\"small\"><strong><font color=\"#200020\">And if the phase 2 documents can be accessed when there is a just cause, the whole seedy racket of jury-rigging clinical trials that we&#8217;ve lived with for several decades will be quickly <em>exposable<\/em>.<\/font><\/strong> The issue of adverse effects is a special case in that the CRFs themselves may be required to determine harms. <\/p>\n<div align=\"justify\" class=\"small\"><strong><font color=\"#200020\">It may be boring, but it&#8217;s damned sure important&#8230;<\/font><\/strong><\/div>\n","protected":false},"excerpt":{"rendered":"<p>I wish that what I write about could always be interesting, but I just can&#8217;t bring it off. Writing is my way of gathering my thoughts, and sometimes that&#8217;s pretty boring, even to me. My daughter who named this blog has apologized for her sarcasm, but to be honest, I&#8217;m very appreciative. The injunction to [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-60787","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/60787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=60787"}],"version-history":[{"count":8,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/60787\/revisions"}],"predecessor-version":[{"id":60796,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/60787\/revisions\/60796"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=60787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=60787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=60787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}